Transplant-associated @entity9818 (TA- @entity10226 ) occurs frequently after hematopoietic stem cell transplantation (HSCT) and can lead to significant morbidity and mortality. There are no data addressing individual susceptibility to TA-TMA. We performed a hypothesis-driven analysis of 17 candidate genes known to play a role in complement activation as part of a prospective study of @entity10226 in HSCT recipients. We examined the functional significance of gene variants by using gene expression profiling. Among 77 @entity1 undergoing genetic testing, 34 had @entity10226 . Sixty-five percent of @entity1 with @entity10226 had genetic variants in at least one gene compared with 9% of @entity1 without @entity10226 (P < .0001). Gene variants were increased in @entity1 of all races with @entity10226 , but nonwhites had more variants than whites (2.5 [range, 0-7] vs 0 [range, 0-2]; P < .0001). Variants in >= 3 genes were identified only in nonwhites with @entity10226 and were associated with high mortality (71%). RNA sequencing analysis of pretransplantation samples showed upregulation of multiple complement pathways in @entity1 with @entity10226 who had gene variants, including variants predicted as possibly benign by computer algorithm, compared with those without @entity10226 and without gene variants. Our data reveal important differences in genetic susceptibility to HSCT-associated @entity10226 based on recipient genotype. These data will allow prospective risk assessment and intervention to prevent @entity10226 in highly susceptible transplant recipients. Our findings may explain, at least in part, racial disparities previously reported in transplant recipients and may guide treatment strategies to improve outcomes.

The genetic fingerprint of susceptibility for transplant-associated XXXX .

@entity9818 :: ('MESH:D057049', 'Disease') :: ['thrombotic microangiopathy'] @entity10226 :: ('CHEBI:166055', 'Chemical') :: ['TMA'] @entity1 :: ('9606', 'Species') :: ['patients']
@entity9818 :: (MESH:D057049,Disease) :: ['thrombotic microangiopathy']
